

Scientists reveal ADHD medication's effect on the brain

January 17 2020, by Dani Ellenby



The fMRI machine located in the IDOR imaging suite. fMRI is used to indirectly detect increased neuronal activity in an area of the brain by measuring higher levels of oxygenated to deoxygenated blood. Credit: Andressa Dias Lemos, IDOR

Attention-deficit hyperactivity disorder (ADHD) is a neurobiological



disorder characterized by symptoms of hyperactivity, inattention and impulsivity. People with the condition are often prescribed a stimulant drug called methylphenidate, which treats these symptoms. However, scientists do not fully understand how the drug works.

Now, researchers at the Okinawa Institute of Science and Technology Graduate University (OIST) have identified how certain areas of the human brain respond to <u>methylphenidate</u>. The work may help researchers understand the precise mechanism of the drug and ultimately develop more targeted medicines for the condition.

Previous research suggests that people with ADHD have different brain responses when anticipating and receiving rewards, compared to individuals without ADHD. Scientists at OIST have proposed that in those with ADHD, neurons in the brain release less dopamine—a 'feelgood' neurotransmitter involved in reward-motivated behavior—when a reward is expected, with dopamine neurons firing more when a reward is given.

"In practice, what this means is that children, or even <u>young adults</u>, with ADHD may have difficulty engaging in behavior that doesn't result in an immediate positive outcome. For example, children may struggle to focus on schoolwork, as it may not be rewarding at the time, even though it could ultimately lead to better grades. Instead, they get distracted by <u>external stimuli</u> that are novel and interesting, such as a classmate talking or traffic noises," said Dr. Emi Furukawa, first author of the study and a researcher in the OIST Human Developmental Neurobiology Unit, led by Professor Gail Tripp.


Scientists believe that methylphenidate helps people with ADHD maintain focus by influencing dopamine availability in the brain. Therefore, Dr. Furukawa and her colleagues set out to examine how the drug affects a brain region called the ventral striatum, which is a vital



component of the reward system and where dopamine is predominantly released.

"We wanted to take a look at how methylphenidate affects the ventral striatum's responses to reward cues and delivery," said Furukawa.

The study, which was recently published in the journal *Neuropharmacology*, was jointly conducted with scientists at D'Or Institute for Research and Education (IDOR) in Rio de Janeiro, Brazil. The collaboration allowed the researchers to combine expertise across multiple disciplines and provided access to IDOR's functional magnetic resonance imaging (fMRI) facility.



When the slot machine showed Cue A – the Japanese character 2 (mi) – participants received money 66% of the time. When the slot machine showed Cue B – the Japanese character 2 (so) – the participants did not receive any money. Credit: OIST



Delving into the brain

The researchers used fMRI to measure <u>brain activity</u> in young adults with and without ADHD as they played a computer game that simulated a slot machine. The researchers scanned individuals in the ADHD group on two separate occasions—once when they took methylphenidate and another time when they took a placebo pill. Each time the reels of the slot machine spun, the computer also showed one of two cues, either the Japanese character [?] (mi) or [?] (so). While familiarizing themselves with the game before being scanned, the participants quickly learned that when the slot machine showed [?], they often won money, but when the slot machine showed [?], they didn't. The symbol [?] therefore acted as a reward-predicting cue, whereas [?] acted as a non-reward-predicting cue.

The researchers found that when individuals with ADHD took the placebo, neuronal activity in the ventral striatum was similar in response to both the reward predicting and non-reward predicting cue. However, when they took methylphenidate, activity in the <u>ventral striatum</u> increased only in response to the reward cue, showing that they were now able to more easily discriminate between the two cues.

The researchers also explored how neuronal activity in the striatum correlated with neuronal activity in the <u>medial prefrontal cortex</u>—a brain region involved in decision-making that receives information from the outside world and communicates with many parts of the brain, including the striatum.

When the individuals with ADHD took placebo instead of methylphenidate, neuronal activity in the striatum correlated strongly with activity in the prefrontal cortex at the exact moment the reward was delivered, and the participants received money from the slot machine




game. Therefore, the researchers believe that in people with ADHD, the striatum and the prefrontal cortex communicate more actively, which may underline their increased sensitivity to rewarding external stimuli. In participants who took methylphenidate, this correlation was low, as it was in people without ADHD.

The results implicate a second neurotransmitter, norepinephrine, in the therapeutic effects of methylphenidate. Norepinephrine is released by a subset of neurons common in the prefrontal cortex. Researchers speculate that methylphenidate might boost levels of norepinephrine in the prefrontal cortex, which in turn regulates dopamine firing in the striatum when rewards are delivered.

"It's becoming clear to us that the mechanism by which methylphenidate modulates the reward response is very complex," said Furukawa.





The red points show the regions examined in the striatum. The researchers calculated correlations between these striatal regions and the medial prefrontal cortex regions shown as blue points. Credit: OIST

Tailoring New Therapies for ADHD

Despite the complexity, the scientists believe that further research could elucidate methylphenidate's mechanism of action, which could benefit



millions of people worldwide.

Pinning down how methylphenidate works may help scientists develop better therapies for ADHD, said Furukawa. "Methylphenidate is effective but has some side effects, so some people are hesitant to take the medication or give it to their children," she explained. "If we can understand what part of the mechanism results in therapeutic effects, we could potentially develop drugs that are more targeted."

Furukawa also hopes that understanding how methylphenidate impacts the brain could help with behavioral interventions. For example, by keeping in mind the difference in <u>brain</u> responses when children with ADHD anticipate and receive rewards, parents and teachers could instead help children with ADHD stay focused by praising them frequently and reducing the amount of distracting stimuli in the environment.

Provided by Okinawa Institute of Science and Technology

Citation: Scientists reveal ADHD medication's effect on the brain (2020, January 17) retrieved 20 January 2023 from <u>https://medicalxpress.com/news/2020-01-scientists-reveal-adhd-medication-effect.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.